Radiopharmaceuticals market

Radiopharmaceuticals in Nuclear Medicine Market, By Product Type (Diagnostic Nuclear Medicine (SPECT Radiopharmaceuticals and PET Radiopharmaceuticals) and Therapeutic Nuclear Medicine), By Application (Oncology, Cardiology, Neurology, Endocrinology, and Others), By End User (Hospitals, Specialty Clinics, and Diagnostic Centers), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027

Request Free Sample

Sep 2020
CMI70
304 Pages
Excel & Pdf
Medical Devices

Summary

There are vast number of radiopharmaceuticals available for diagnostic as well therapeutic purposes, each with different as well as same indications for certain diseases such as Alzheimer's (Vizamyl, Amyvid, and Neuraceq). There are around 50 U.S. FDA approved radiopharmaceuticals available for diagnostic as well as therapeutic use and Technetium alone has over 30 approved products available for diagnosis purposes.

Areas where radiopharmaceuticals have applications include oncology, neurology, hematology, cardiology, thyroid applications, and others. Oncology applications include cancer diagnosis and treatment effectivity determination (using radiolabeled therapeutics). Moreover, basic cancer physiology detection is also possible with the help of these radiopharmaceuticals. For instance, Fluorine-18 fludeoxyglucose is indicated for assessing abnormal glucose metabolism in tumors

The global radiopharmaceuticals in nuclear medicine market is estimated to be valued at US$ 6,700.5 million in 2020 and is expected to exhibit a CAGR of 8.0% over the forecast period (2020-2027).

Figure 1. Global Radiopharmaceuticals in Nuclear Medicine Market Share (%) in Terms of Value, By Region, 2020

Increasing product approvals by regulatory authorities is expected to propel the market growth over the forecast period

Key players operating in the market are focusing on obtaining approvals, which is expected to drive the market growth over the forecast period. For instance, in February 2018, NorthStar Medical Radioisotopes, LLC received the U.S. FDA approval for its RadioGenix System, an innovative, high-tech radioisotope separation platform indicated for use in producing widely-used medical radioisotope technetium-99 (Tc-99m) from NorthStar’s non-uranium based molybdenum-99 (Mo-99).

Figure 2. Global Radiopharmaceuticals in Nuclear Medicine Market Share (%) in Terms of Value, By Application, 2020

Adoption of inorganic growth strategies by key players is expected to drive the market growth over the forecast period

Market players are focused on adoption of inorganic growth strategies such as mergers and acquisitions to strengthen their position in the global radiopharmaceuticals in nuclear medicine market. For instance, in 2017, Cardinal Health, Inc. acquired North American rights of Lymphoseek, a radiopharmaceutical diagnostic imaging agent, from Navidea Biopharmaceuticals, Inc. Navidea received around US$ 83 million at closing and will have the opportunity to earn up to US$ 227 million of contingent consideration based on certain milestones through 2026, with US$ 17.1 million of that amount guaranteed over the next three years.

Radiopharmaceuticals in Nuclear Medicine Market Report Coverage

Report Coverage	Details
Base Year:	2019	Market Size in 2019:	US$ 6,700.5 Mn
Historical Data for:	2016 to 2019	Forecast Period:	2020 to 2027
Forecast Period 2020 to 2027 CAGR:	8.0%	2027 Value Projection:	US$ 11,504.8 Mn
Geographies covered:	North America: U.S. and Canada Latin America: Brazil, Argentina, Mexico, and Rest of Latin America Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific Middle East: GCC, Israel, and Rest of Middle East Africa: South Africa, North Africa, and Central Africa
Segments covered:	By Product Type: Diagnostic Nuclear Medicine: SPECT Radiopharmaceuticals, PET Radiopharmaceuticals. Therapeutic Nuclear Medicine. By Application: Oncology, Cardiology, Neurology, Endocrinology, Others. By End User: Hospitals, Specialty Clinics, Diagnostic Centers.
Companies covered:	Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.
Growth Drivers:	Increasing product approvals by regulatory authorities Adoption of inorganic growth strategies by key players
Restraints & Challenges:	High cost of development of radiopharmaceuticals relative to return on investment Supply shortage of radiopharmaceuticals

Global Radiopharmaceuticals in Nuclear Medicine Market – Impact of Coronavirus (Covid-19) Pandemic

Following the outbreak of COVID-19 in December 2019, the disease has spread to over 100 countries across the globe and the World Health Organization has declared it a public health emergency. According to the World Health Organization’s report, the manifestation of coronavirus (COVID-19) has resulted in more than 27.8 million infected individuals worldwide as of September 2020.

Coronavirus pandemic has negatively impacted the development, production, and supply of nuclear medicines and also affected growth of the radiopharmaceutical businesses of various companies across the globe, as COVID-19 pandemic has led to lockdown in several countries, globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities and disruption in supply chain of the radiopharmaceuticals and kits for diagnostic and therapeutic use.

Most of the oncologists and cancer research institutes in major countries such as the U.S., Canada, and other low-and-middle income countries, which are largely dependent on radioisotope suppliers, have faced issues related to radiopharmaceutical supply and difficulty in access to therapeutic tracers such as 123I, 123I-MIBG, and 131I-MIBG. This is due to cost and transportation issues faced by suppliers and distributors. Moreover, nuclear medicine manufacturers also face issues in obtaining cold kits, which are used to simplify radiopharmaceutical production.

Radiopharmaceuticals in Nuclear Medicine Market: Restraints

Nuclear medicine field is heavily dependent on availability of Technetium-99m for diagnostic use and according to International Atomic Energy Agency (IAEA), 2014, Tc-99m is used in 20-40 million scans every year globally, which is almost 75 per cent of all procedures in nuclear medicine.

As these isotopes are supplied by reactors present across the world, repeated and prolonged closures of one or more of these nuclear reactors have led to ongoing fluctuations in isotope availability (more prominently after 2007, as the National Research Universal (NRU) in Chalk River, Ontario was shut down in May 2009). Similarly, on March 31, 2018, the National Research Universal (NRU) nuclear reactor in Chalk River, Ontario, Canada went offline for the final time and the Osiris reactor in France shut down at the end of 2015. Such events are expected to restrain growth of the market over the forecast period.

Furthermore, high cost of development of radiopharmaceuticals relative to return on investment is also expected to restrain growth of the radiopharmaceuticals in nuclear medicine market. According to the National Center for Biotechnology Information studies (2006), the cost of developing a drug for diagnostic imaging to commercialization is in the range of US$ 100 to US$ 200 million, which is still applicable today according to a study by the Society of Nuclear Medicine and Molecular Imaging, Inc. (2019).

Key Players

Major players operating in the global radiopharmaceuticals in nuclear medicine market include Progenics Pharmaceuticals, Inc., NorthStar Medical Radioisotopes LLC, Curium Pharma, Life Molecular Imaging, Lantheus Holdings, Inc., Cardinal Health, Inc., General Electric Company, Bracco S.p.A., Bayer AG, Advanced Accelerator Applications, S.A., Eli Lilly and Company, Nihon Medi-Physics. Co. Ltd., FUJIFILM Toyama Chemical Co., Ltd., Jubilant Life Sciences Ltd., Samyoung Unitech, and DuChemBio, Inc.

Table of Content

*Browse 56 market data tables and 50 figures on "Radiopharmaceuticals in Nuclear Medicine Market” - Global forecast to 2027

N/A

- Frequently Asked Questions -

What are the growth estimates for the global radiopharmaceuticals in nuclear medicine market till 2027?

The global radiopharmaceuticals in nuclear medicine market size is estimated to surpass US$ 11,504.8 million by 2027.

What will be the compound annual growth rate (CAGR) for the global radiopharmaceuticals in nuclear medicine market during the forecast period?

The global radiopharmaceuticals in nuclear medicine market is expected to register a CAGR of 8.0% during the forecast period (2020-2027).

What are the major drivers for the global radiopharmaceuticals in nuclear medicine market?

Increasing product approvals by regulatory authorities and adoption of inorganic growth strategies by key players are driving the global radiopharmaceuticals in nuclear medicine market growth.

Which segment, based on product type, is estimated to account for the largest market share in the global radiopharmaceuticals in nuclear medicine market in 2020?

The diagnostic nuclear medicine segment is estimated to hold major market share in 2020, owing to owing to increasing product launches for radiopharmaceuticals in nuclear medicine by market players.

What are the key factors hampering growth of the market?

Major factor hampering growth of the market is high cost of development of radiopharmaceuticals relative to return on investment, and supply shortage of radiopharmaceuticals.

Radiopharmaceuticals market

Radiopharmaceuticals in Nuclear Medicine Market Report Coverage

Table of Contents

- Frequently Asked Questions -

What are the growth estimates for the global radiopharmaceuticals in nuclear medicine market till 2027?

What will be the compound annual growth rate (CAGR) for the global radiopharmaceuticals in nuclear medicine market during the forecast period?

What are the major drivers for the global radiopharmaceuticals in nuclear medicine market?

Which segment, based on product type, is estimated to account for the largest market share in the global radiopharmaceuticals in nuclear medicine market in 2020?

What are the key factors hampering growth of the market?

Which are the major players operating in the market?

Reliability and reputation

Secure Payments By: